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To the Editor 
The coronavirus disease 2019 (COVID-19) pandemic poses the most significant modern-day 
public health challenge since the Spanish flu of 1918, causing substantial morbidity and mortality 
worldwide.(1) Coronavirus disease 2019 predominantly affects the respiratory system, causing severe 
pneumonia and respiratory distress syndrome. There is also involvement of multiple organs, and the 
cardiovascular system has been implicated. In a recent study to investigate characteristics and 
prognostic factors in 339 elderly patients with COVID-19, Wang and colleagues observed a high 
proportion of severe and critical cases as well as high fatality rates.(2) The cardiovascular 
complications recorded were acute cardiac injury (21%), arrhythmia (10.4%) and cardiac 
insufficiency (17.4%). However, not all cardiovascular manifestations of COVID-19 are clearly 
defined by published studies and it is also not clear if these conditions are directly caused by COVID-
19 or are just unspecific complications.(3) There is a need to understand the interplay between 
COVID-19 and its cardiovascular manifestations to assist in the optimum management of patients. In 
this context, we conducted a systematic meta-analysis to attempt to address the following questions: 
(i) what are the cardiovascular complications associated with COVID-19?; (ii) what is the incidence 
of these complications?;  and (iii) are patients with pre-existing cardiovascular morbidities more 
susceptible to these cardiovascular complications? 
The protocol for this review was registered in the PROSPERO International prospective 
register of systematic reviews (CRD42020184851). The review was conducted in accordance with 
PRISMA and MOOSE guidelines (4, 5) (Supplementary Materials 1-2). We searched MEDLINE, 
Embase, and The Cochrane library from 2019 to 27 May 2020 for published studies reporting on 
cardiovascular outcomes in patients with COVID-19. Details of the search strategy are reported in 
Supplementary Material 3. The prevalence of comorbidities (pre-existing hypertension and 
cardiovascular disease, CVD) and incidence of cardiovascular complications across studies with their 
95% confidence intervals (CIs) were pooled using Freeman-Tukey variance stabilising double arcsine 
transformation and random-effects models. STATA release MP 16 (StataCorp LP, College Station, 




Seventeen retrospective cohort studies comprising of 5,815 patients with COVID-19 were 
included (Table 1; Supplementary Materials 4-5). Eleven studies were based in China, four in the 
USA, one in South Korea and one in the Netherlands. The average age at baseline ranged from 47 to 
71 years. 
Across 15 studies, the pooled prevalence of pre-existing hypertension (95% CI) in COVID-19 
patients was 29.3% (25.5-33.4; I2 =87%; 95% CI 79, 91%; p for heterogeneity<0.01) 
(Supplementary Material 6). The prevalence (95% CI) of pre-existing CVD across 16 studies was 
14.6% (11.0-18.4; I2 =91%; 95% CI 87, 94%; p for heterogeneity<0.01) (Supplementary Material 
7).  
Over hospital stays ranging from 2 to 28 days, the pooled incidence was 17.6% (14.2-21.2; I2 
=32%; 95% CI 0, 76%; p for heterogeneity=0.20) for heart failure (HF) (n=4 studies); 16.3% (11.8-
21.3; I2 =87%; 95% CI 79, 92%; p for heterogeneity<0.01) for myocardial injury (n=11 studies); 9.3% 
(5.1-14.6; I2 =78%; 95% CI 52, 90%; p for heterogeneity<0.01) for cardiac arrhythmia (n=6 studies); 
6.2% (1.8-12.3) for acute coronary syndrome (ACS) (n=2 studies); 5.7% (2.7-9.6) for cardiac arrest 
(n=2 studies); and 5.6% (3.4-8.3) for disseminated intravascular dissemination (DIC) (n=2 studies) 
(Figure 1A). Subgroup analyses suggested that the incidence of myocardial injury was higher in older 
age groups and groups with a higher prevalence of pre-existing hypertension; however, the incidence 
of myocardial injury was similar in groups with high or low prevalence of pre-existing CVD (Figure 
1B). Over hospital stays ranging from 2 to 28 days following admission, mortality rate ranged from 
0.7% to 52.4%, with a pooled rate of 15.3% (10.7-20.5). 
The current data based on up-to-date evidence suggests that the most common cardiovascular 
complications of COVID-19 are HF, myocardial injury and cardiac arrhythmias. Though the 
mechanisms for cardiovascular complications are still yet to be elucidated, the following multiple 
pathways have been proposed: (i) direct cardiotoxicity; (ii) systemic inflammation; (iii) myocardial 
demand-supply mismatch; (iv) plaque rupture and coronary thrombosis; (v) adverse effects of 
therapies during hospitalization; (vi) sepsis leading to DIC; (vii) increased systemic thrombogenesis; 
and (viii) electrolyte imbalances.(6, 7) Myocardial injury is reported to mainly result from direct viral 




thromboembolism incidence was based on a single report, patients with COVID-19 are at increased 
risk of hypercoagulable states due to prolonged immobilisation, systemic inflammation and risk for 
DIC.(7) 
In addition to pre-existing comorbidities including CVD being associated with worse 
outcomes in patients with COVID-19,(8, 9) cardiovascular complications such as myocardial injury 
have also been shown to be associated with increased risk of severe COVID-19 and fatal 
outcomes.(10) Myocardial injury is commonly defined as substantial elevation of high-sensitivity 
cardiac troponin levels and it has been reported that elevated troponin levels are associated with 
greater risk of severe disease and mortality. (10) Monitoring of markers of cardiac damage such as 
troponin, N-terminal pro B-type natriuretic peptide and creatine kinase during hospitalisation for 
COVID-19 could help in the identification of patients with possible cardiac manifestations, to enable 
early and more aggressive intervention.  
The inherent limitations included the low sample sizes and  methodological design of some of 
the studies, which was expected given the urgency to report and  gain a better understanding of 
COVID-19; limited number of studies available, hence some of the findings were based on single 
reports; assays for cardiac injury and their time of assessment during hospitalisation may vary 
between studies, hence estimates may be biased; and the possibility of patient overlap given that the 
majority of studies were conducted from China and reports of duplicate publication of study 
participants in articles.(9)  
Aggregate analysis of the literature suggests that the most frequent cardiovascular 
complications among patients hospitalised with COVID-19 are HF, myocardial injury, cardiac 
arrhythmias and ACS. Early identification and monitoring of cardiac complications could help in the 
prediction of more favourable outcomes. The causes of these cardiovascular manifestations warrant 
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Table 1. Characteristics of included studies 
Author, year of 
publication 
Source of data Country Dates of data collection Mean/median 
age (years) 




CVD complications NOS 
Guo, 2020 Seventh Hospital of Wuhan City China Jan - Feb 2020 58.5 48.7 16.3 187 Myocardial injury; 
ventricular arrhythmia 
5 
Wang, 2020 Zhongnan Hospital of Wuhan University China Jan, 2020 56.0 54.3 7.0 138 Myocardial injury; cardiac 
arrhythmia 
4 
Huang, 2020 Jin Yintan Hospital, Wuhan China Dec - Jan 2020 49.0 73.0 7.0 41 Myocardial injury 4 
Zhou, 2020 Jinyintan Hospital & Wuhan Pulmonary Hospital China Dec - Jan 2020 56.0 62.0 11.0 191 Myocardial injury; HF 5 
Shi,2020 Renmin Hospital of Wuhan University China Jan - Feb 2020 64.0 49.3  NR 416 Myocardial injury 6 
Arentz, 2020 Evergreen Hospital in Kirkland, Washington USA Feb - March 2020 70.0 52.0 5.2 21 Cardiomyopathy 4 
Chen, 2020 Tongji Hospital in Wuhan China Jan - Feb 2020 62.0 62.0 13.0 274 Myocardial injury; HF; DIC 4 
Du, 2020 Hannan Hospital and Wuhan Union Hospital China Jan - Feb 2020 65.8 72.9 10.1 85 Cardiac arrest; ACS; 
arrhythmia; DIC 
4 
Wang, 2020b Renmin Hospital of Wuhan University China Jan - Feb 2020 71.0 49.0 28.0 339 Myocardial injury, 
arrhythmia HF 
4 
Cao, 2020 Zhongnan Hospital of Wuhan University China Jan - Feb 2020 54.0 52.0 11.0 102 Myocardial injury; 
arrhythmia; cardiac arrest 
4 
Klok, 2020 Dutch Univesity Hospitals Netherlands March - April 2020 64.0 76.0 7.0 184 PE; VTE; stroke 4 
Aggarwal, 2020 UnityPoint Clinic USA March - April 2020 67.0 75.0 2.0 16 ACS; cardiac arrhythmia; HF 4 
Wang, 2020c Zhongnan Hospital of Wuhan University and Xishui People’s 
Hospital 
China Up to Feb, 2020 51.0 53.3 11.0 107 Myocardial injury 5 
Hong, 2020 Yeungnam University Medical Center South Korea Up to March, 2020 55.4 38.8 7.7 98 Myocardial injury 4 
Wan, 2020 Northeast Chongqing China Jan – Feb 2020 47.0 53.3 5.0 135 Myocardial injury 4 
Price-Haywood, 
2020 
Ochsner Health in Louisiana Asia March – April, 2020 55.5 45.7 7.0 1,030 Cardiomyopathy/HF 6 
Price-Haywood, 
2020 
Ochsner Health in Louisiana Asia March – April, 2020 53.6 37.7 6.0 2,451 Cardiomyopathy/HF 6 
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No Checklist item 
Reported on page 
No 
Title 




2 Provide a structured summary including, as applicable, background, objectives, data sources, study 
eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, 
conclusions and implications of key findings, systematic review registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known Introduction 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 





5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, 
provide registration information including registration number 
Methods 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years 
considered, language, publication status) used as criteria for eligibility, giving rationale 
Methods 
Information sources 7 Describe all information sources (such as databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched 
Methods 




Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if 




10 Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators 
Methods 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any 
assumptions and simplifications made 
Methods 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether 
this was done at the study or outcome level), and how this information is to be used in any data synthesis 
Methods 
Summary measures 13 State the principal summary measures (such as risk ratio, difference in means). Methods 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (such as I2 statistic) for each meta-analysis 
Methods 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, 
selective reporting within studies) 
Methods 
Additional analyses 16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified 
Methods 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 






18 For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up 
period) and provide the citations 
Results, Table 1 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12). Results  
Results of 
individual studies 
20 For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each 
intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot 
 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency Results, Figure 1; 
Supplementary 
materials 6-7 
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see item 15) Not applicable 






24 Summarise the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (such as health care providers, users, and policy makers) 
Discussion 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as 
incomplete retrieval of identified research, reporting bias) 
Discussion 




Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and role 





Supplementary Material 2. MOOSE checklist  
 
Cardiovascular complications in COVID-19: A systematic review and meta-analysis 
 
 
Criteria Brief description of how the criteria were handled in the review 
Reporting of background   
 Problem definition Cardiovascular manifestations of COVID-19 are not clearly defined. 
 Hypothesis statement (i) What are the cardiovascular complications associated with COVID-19? 
(ii) What is the incidence of these complications? 
(iii) Are patients with pre-existing cardiovascular morbidities more 
susceptible to these cardiovascular complications? 
 
 Description of study outcomes Cardiovascular complications 
 Type of exposure  Prevalence and incidence estimates 
 Type of study designs used Observational cohort designs and clinical studies 
 Study population Adult patients with COVID-19 
Reporting of search strategy should include  
 Qualifications of searchers Setor K. Kunutsor, PhD 
 Search strategy, including time period 
included in the synthesis and keywords 
Time period: from inception to 27 May 2020 
The detailed search strategy can be found in Supplementary material 3 
 Databases and registries searched MEDLINE, Embase and The Cochrane Library 
 Search software used, name and version, 
including special features 
OvidSP was used to search Embase and MEDLINE 
EndNote X9 used to manage references  
 Use of hand searching We searched bibliographies of retrieved papers  
 List of citations located and those 
excluded, including justifications 
Details of the literature search process are outlined in the flow chart.  The 
citation list for excluded studies are available on request. 
 Method of addressing articles published 
in languages other than English 
Not applicable 
 Method of handling abstracts and 
unpublished studies 
Not applicable 
 Description of any contact with authors None 
Reporting of methods should include  
 Description of relevance or 
appropriateness of studies assembled for 
assessing the hypothesis to be tested 
Detailed inclusion and exclusion criteria are described in the Methods 
section. 
 Rationale for the selection and coding of 
data 
Data extracted from each of the studies were relevant to the population 
characteristics, study design, exposure, and outcome. 
 Assessment of confounding We assessed confounding by ranking individual studies on the basis of 
different adjustment levels and performed sub-group analyses to evaluate 
differences in the overall estimates according to levels of adjustment. 
 Assessment of study quality, including 
blinding of quality assessors; 
stratification or regression on possible 
predictors of study results 
Study quality was assessed based on the nine-star Newcastle–Ottawa Scale 
using pre-defined criteria namely: population representativeness, 
comparability (adjustment of confounders), ascertainment of outcome. 
Sensitivity analyses by several quality indicators such as study size, duration 
of follow-up, and adjustment factors. 
 Assessment of heterogeneity Results 
 Description of statistical methods in 
sufficient detail to be replicated 
Described in methods section 
 Provision of appropriate tables and 
graphics 
Table 1; Figure 1; Supplementary materials 6-7 
Reporting of results should include  
 Graph summarizing individual study 
estimates and overall estimate 
Supplementary materials 6-7 
 Table giving descriptive information for 
each study included 
Table 1 
 Results of sensitivity testing 
 
Not applicable  
 Indication of statistical uncertainty of 
findings 
95% confidence intervals were presented with all summary estimates 
Reporting of discussion should include  






 Justification for exclusion All studies were excluded based on the pre-defined inclusion criteria in 
methods section. 
 Assessment of quality of included studies Brief discussion included in ‘Methods’ section 
Reporting of conclusions should include  
 Consideration of alternative explanations 
for observed results 
Discussion 
 Generalization of the conclusions Discussed in the context of the results. 
 Guidelines for future research We recommend large-scale studies when more data becomes available 






Supplementary Material 3: MEDLINE literature search strategy 
 
1     COVID-19.mp. (3926) 
2     SARS-CoV-2.mp. (1044) 
3     exp Cardiovascular Diseases/ (2362814) 
4     exp Arrhythmias, Cardiac/ (207163) 
5     exp Atrial Fibrillation/ (54365) 
6     exp Ventricular Fibrillation/ (16940) 
7     ventricular tachyarrhythmia.mp. (1239) 
8     cardiac injury.mp. (3702) 
9     myocardial injury.mp. (8353) 
10     exp Myocardial Infarction/ (173824) 
11     exp Acute Coronary Syndrome/ (15265) 
12     exp Acute Coronary Syndrome/ (15265) 
13     exp Myocarditis/ (14391) 
14     exp Cardiomyopathies/ (93121) 
15     exp Heart Failure/ (119900) 
16     exp Venous Thromboembolism/ (10498) 
17     exp Pulmonary Embolism/ (38540) 
18     exp Disseminated Intravascular Coagulation/ (10958) 
19     1 or 2 (4030) 
20     3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (2374706) 
21     19 and 20 (105) 
22     limit 21 to (english language and humans and yr="2019 -Current") (80) 
 
 





Supplementary Material 4: Selection of studies included in the meta-analysis 
144 Potentially relevant citations identified
From MEDLINE, Embase and reference list 
of relevant studies
126 excluded on the basis of title 
and/ or abstract
2 Articles excluded due to:
1 Population not relevant
1 Outcome not relevant
16 Articles (comprising of 17 studies) 
included in review
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Supplementary Material 6: Prevalence of pre-existing hypertension in COVID-19 patients 
 

















































































Supplementary Material 7: Prevalence of pre-existing cardiovascular disease in COVID-19 patients 
 
















































































CI, confidence interval (bars) 
 
 
